Blocking the GLP-1 receptor with exendin(9-39) eliminates the improvements in insulin sensitivity and blood glucose control caused by liraglutide in people with obesity and prediabetes, indicating...

Pro

Against

Mechanism

Synthesis from 1 study

How it works

When a drug activates a specific receptor in the body, it tells the liver to stop making too much sugar, tells the pancreas to release less of a hormone that raises blood sugar, and helps muscles and fat absorb sugar better. If you block that same receptor, all those improvements vanish — proving...

Most probable mechanism

In Simple Terms

A drug that mimics a natural hormone binds to specific receptors on the liver, muscle, and pancreas, which tells the liver to make less sugar, tells the pancreas to release less of another hormone that raises blood sugar, and helps the body’s tissues absorb sugar more efficiently — when this receptor is blocked, all these benefits disappear.

Causal chain

A GLP-1 receptor agonist binds to and activates GLP-1 receptors on pancreatic alpha cells, directly inhibiting glucagon secretion.

Verified by multiple studies

which leads to

Reduced glucagon levels decrease hepatic glucose production through suppressed gluconeogenesis and glycogenolysis.

Verified by multiple studies

which leads to

GLP-1 receptor activation on hepatocytes and skeletal muscle enhances insulin signaling pathways, increasing glucose uptake and reducing insulin resistance.

Verified by multiple studies

which leads to

GLP-1 receptor antagonism reverses glucagon suppression and insulin sensitization, restoring elevated glucose levels and impaired glucose tolerance.

Verified by multiple studies

Evidence from Studies

Supporting (1)

Community contributions welcome

Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes.

Randomized Controlled Trial

Human

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes.

Score: 89

DOI: 10.2337/db23-0356

Similar Assertions

Blocking the GLP-1 receptor with exendin(9-39) eliminates the improvements in insulin sensitivity and blood glucose control that result from liraglutide treatment in people with obesity and prediabetes, indicating that these effects require GLP-1 receptor activity.

99%

In people with obesity and prediabetes, the drug liraglutide lowers blood glucose levels after fasting and after meals within two weeks, even without weight loss. This effect is not seen with other approaches that increase GLP-1 naturally or reduce calories, suggesting liraglutide works through a distinct mechanism.

80%

In people with obesity and prediabetes, a drug called sitagliptin raises levels of certain gut hormones but does not improve how the body responds to insulin or lower fasting blood sugar. This differs from another drug, liraglutide, which activates the same hormone receptors directly and does affect these measures.

80%

In people with obesity and prediabetes, a daily dose of liraglutide improves how the body responds to insulin within two weeks, before any significant weight loss occurs, and this improvement is blocked when the GLP-1 receptor is inhibited.

79%

In people with obesity and prediabetes, the drug liraglutide lowers blood glucose levels after eating and in the fasted state within two weeks, even without weight loss, and these effects are not seen with other approaches like sitagliptin or dieting alone.

77%